ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tretinoin Gel Microsphere, 0.04%

Also written as “Tretinoin Gel Microsphere, 0.1%”.

Its studies are mostly in Acne Vulgaris, led by Sun Pharmaceutical Industries.

Furthest: phase 1, since Mar 9, 20262 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries20 open or runningphase 1since Mar 9, 2026May 7, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2021First study: early phase 1 study in Acne VulgarisFirst studyNCT04883736 · 973 enrolled · United States
  2. Mar 9, 2026Phase 1 study in Acne VulgarisNCT07469228 · 1,043 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07469228Acne Vulgaris · United States1CompletedDec 15, 20251,043
NCT04883736Acne Vulgaris · United StatesEarly 1CompletedApr 16, 2021973

How it is read

Names in the registry

  • “Tretinoin Gel Microsphere, 0.04%”, 1 entry
  • “Tretinoin Gel Microsphere, 0.1%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.